BioCentury
ARTICLE | Regulation

Trio of approvals includes Seattle Genetics’ breast cancer therapy

Incyte’s Pemazyre pemigatinib approved for cholangiocarcinoma; Everest gains first approval via Singapore

April 18, 2020 1:32 AM UTC

Just two months after granting Priority Review to Seattle Genetics’ Tukysa tucatinib, FDA approved the drug as part of a triple combo to treat breast cancer, marking one of a trio of approvals Friday.

Incyte and Everest also announced approvals. ...